+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antithymocyte globulin for steroid resistant rejection in renal transplant recipients immunosuppressed with triple therapy



Antithymocyte globulin for steroid resistant rejection in renal transplant recipients immunosuppressed with triple therapy



Transplant International 2(1): 27-32



Steroid resistant rejection, confirmed histologically, occurred in 35 of 187 consecutive cadaveric renal transplants treated with triple therapy (cyclosporin, azathioprine and prednisolone) in the Oxford Transplant Unit. Twenty-seven of these were treated with a rabbit antithymocyte globulin (ATG) and 19 showed recovery of function. The level of serum creatinine, the renal biopsy appearance and the requirement for dialysis at the start of ATG treatment did not predict which patients would respond to the therapy. One year after transplantation there was no significant difference between the mean plasma creatinine levels of those patients with steroid resistant rejection who had been given ATG and responded (151.6 mumol/l) and those who had responded to steroids alone (165.0 mumol/l). Adverse effects of ATG treatment included a mean fall in white cell count of 62.2% and a mean fall in platelet count of 45.1%. Two of the 27 patients who received ATG died (7.4% mortality). ATG would appear to be an effective treatment of steroid resistant rejection in patients receiving triple therapy immunosuppression, and graft function may subsequently be excellent in those patients who respond to treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039304547

Download citation: RISBibTeXText

PMID: 2669801

DOI: 10.1007/bf02425968


Related references

Use of antithymocyte globulin and cyclosporine to treat steroid-resistant rejection episodes in renal transplant recipients. Transplantation Proceedings 19(1 Pt 3): 1889-1891, 1987

Antilymphoblast globulin treatment of steroid-resistant rejection in cyclosporine-immunosuppressed renal transplant recipients. Transplantation Proceedings 19(1 Pt 3): 1892, 1987

Cyclosporine and okt 3 salvage for steroid resistant and antithymocyte globulin resistant renal transplant rejection. Transplantation Proceedings 17(6): 2748-2750, 1985

A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients. Transplantation 97(4): 470-473, 2014

Rabbit anti-thymocyte globulin treatment of steroid resistant rejection in renal allograft recipients immunosuppressed with cyclosporine A. Transplantation Proceedings 21(1 Pt 2): 1736-1737, 1989

Rejection-free experience using rabbit antithymocyte globulin in renal transplant recipients. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 769A-770A, 2002

Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation. Transplantation Proceedings 25(1 Pt 2): 1436-1438, 1993

Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplantation Proceedings 38(5): 1307-1313, 2006

Pretransplant thymic function predicts acute rejection in antithymocyte globulin-treated renal transplant recipients. Kidney International 89(5): 1136-1143, 2017

Do Antithymocyte Globulin-Free Acute Rejection Therapies Increase the Risk of Polyoma Nephropathy in Renal Transplant Recipients?. Transplantation Proceedings 51(4): 1112-1114, 2019

Atrial fibrillation in renal allograft recipients under antithymocyte globulin therapy for acute rejection. JN Journal of Nephrology 8(1): 53-56, 1995

Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal. PharmacoTherapy 31(6): 566-573, 2012

Reversal of steroid- and antithymocyte globulin-resistant acute rejection crises in renal transplantation with monoclonal antibody (OKT3). Transplantation Proceedings 22(4): 1753-1754, 1990

Antithymocyte globulin-induced prolongation of human renal allograft survival in recipients with in vitro steroid-resistant ADCC. Transplantation Proceedings 16(6): 1503-1505, 1984

Value of cyclosporine measurements in renal transplant recipients immunosuppressed with triple therapy. Transplantation Proceedings 22(3): 1251-1252, 1990